Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + Chemo for Newly Diagnosed CNS Lymphoma
NCT07405255Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Ruijin Hospital. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT07405255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405255.